RESUMEN
The uterus is an unusual site for metastasis from an extrapelvic neoplasm. Metastasis of gastric cancer to the uterus is rare. We experienced a patient who underwent a gastrectomy and chemotherapy due to gastric cancer and who subsequently suffered a solitary metastatic adenocarcinoma of the uterus from the primary gastric cancer. Similar to Krukenberg tumors of the ovary, lymphatic dissemination is regarded as the route of metastasis from the stomach to the uterine. We report this case with a brief review of literature.
Asunto(s)
Femenino , Humanos , Adenocarcinoma , Quimioterapia , Gastrectomía , Tumor de Krukenberg , Metástasis de la Neoplasia , Ovario , Estómago , Neoplasias Gástricas , ÚteroRESUMEN
The uterus is an unusual site for metastasis from an extrapelvic neoplasm. Metastasis of gastric cancer to the uterus is rare. We experienced a patient who underwent a gastrectomy and chemotherapy due to gastric cancer and who subsequently suffered a solitary metastatic adenocarcinoma of the uterus from the primary gastric cancer. Similar to Krukenberg tumors of the ovary, lymphatic dissemination is regarded as the route of metastasis from the stomach to the uterine. We report this case with a brief review of literature.
Asunto(s)
Femenino , Humanos , Adenocarcinoma , Quimioterapia , Gastrectomía , Tumor de Krukenberg , Metástasis de la Neoplasia , Ovario , Estómago , Neoplasias Gástricas , ÚteroRESUMEN
OBJECTIVE: Chemotherapy of ovarian cancer has a main role in the post-surgical treatment of ovarian cancer. However, relapsing patients are usually resistant to an additional chemotherapy. The development of immunotherapy is therefore needed to offer other preventive treatment modalities of ovarian cancer. MAGE encoding tumor-rejection antigens recognized by cytotoxic T lymphocytes are expressed at the mRNA level in various malignant tumors. We investigated the possibility of immunotherapy of ovarian cancer of MAGE expression. METHODS: To explore this possibility in ovarian tumors, we investigated the expression of MAGE 1-6 in 44 surgical samples of neoplastic and non-neoplastic tissues from ovaries using a MAGE 1-6 common primer by the nested reverse transcription-polymerase chain reaction (nested RT-PCR) and DNA sequencing after subcloning of PCR products. The material consisted of 5 cases of normal ovaries, 6 cases of non- neoplastic diseases (3 follicular cysts, 2 endometrioses, and 1 tuboovarian abscess), and 8 cases of benign serous, 4 cases of mucinous cystic tumor, 9 teratomas, and 4 cases of malignant serous tumor, 1 case of mucinous tumor, 2 cases of undifferentiated carcinoma, 2 borderline serous and 3 mucinous tumor. RESULTS: MAGE were expressed in 23% of benign ovarian tumors (5/21 cases). In contrast, no expression of these genes was observed in any of the 11 samples of normal and non-neoplastic ovarian tissues. All (92%) malignant tumors except one case of borderline malignant mucinous tumor showed MAGE 1-6 m RNA expression (P<0.05). The isotype of MAGE were confirmed in 5 cases for MAGE-3 (31.2%), 4 cases of MAGE-4 (25%), 2 cases of MAGE A1 (12.5%) and A 4b (12.5%), and one case of MAGE A2, 4a, combined A3 and A6, and A4 and 4b. CONCLUSION: We concluded that the expression of MAGE could be used as a target for tumor specific immunotherapy in ovarian cancer expressing MAGE.
Asunto(s)
Femenino , Humanos , Carcinoma , Quimioterapia , Endometriosis , Quiste Folicular , Inmunoterapia , Mucinas , Neoplasias Ováricas , Ovario , Reacción en Cadena de la Polimerasa , ARN , ARN Mensajero , Análisis de Secuencia de ADN , Linfocitos T Citotóxicos , TeratomaRESUMEN
The measurement of tumor cell proliferation is becoming inueasingly recognized in defining prognostic groups. Boliferatirg cell nuclear antigen(PCNA) imrnunolocalimtion can be used as an index of cell proliferation and rnay define the extent of deppature from norrmil gmwth control. PCNA is eonsidered to be maker of cell proliferation. The aim of this study was to evnlunte the expreeion of PCNA in epithelial ocarian cancer as well as the possible correlation with degree of differentiation, tumor etage and overall survival. The material consisted of 35 epithehal ovarian cancer. The PCNA labelling index (Ll) ranged from 7.5% to 92.5% with a median value of 46.7%. PCNA labelling index (LI) is 30% in grade 1, 63% in grade 2, and 100% in grade 3 in epithelial ovarian cancer(p>0.05). Also, a positive correlation was found between PCNA labelling index (LI) and clinical stage (P<0.05) The estimated 3 year survival in patients with a tumor LI below the median (low proliferative group) was higher than those with a tumor LI greater than the median(high proliferation group) (87.5% VS 50%, P<0.05).
Asunto(s)
Humanos , Proliferación Celular , Neoplasias Ováricas , Pronóstico , Antígeno Nuclear de Célula en ProliferaciónRESUMEN
The measurement of tumor cell proliferation is becoming inueasingly recognized in defining prognostic groups. Boliferatirg cell nuclear antigen(PCNA) imrnunolocalimtion can be used as an index of cell proliferation and rnay define the extent of deppature from norrmil gmwth control. PCNA is eonsidered to be maker of cell proliferation. The aim of this study was to evnlunte the expreeion of PCNA in epithelial ocarian cancer as well as the possible correlation with degree of differentiation, tumor etage and overall survival. The material consisted of 35 epithehal ovarian cancer. The PCNA labelling index (Ll) ranged from 7.5% to 92.5% with a median value of 46.7%. PCNA labelling index (LI) is 30% in grade 1, 63% in grade 2, and 100% in grade 3 in epithelial ovarian cancer(p>0.05). Also, a positive correlation was found between PCNA labelling index (LI) and clinical stage (P<0.05) The estimated 3 year survival in patients with a tumor LI below the median (low proliferative group) was higher than those with a tumor LI greater than the median(high proliferation group) (87.5% VS 50%, P<0.05).